Resultados da busca - David D. Stenehjem

  • Mostrando 1 - 8 resultados de 8
Refinar Resultados
  1. 1
    Panobinostat for the treatment of multiple myeloma: the evidence to date

    Panobinostat for the treatment of multiple myeloma: the evidence to date por Sunil Sharma, Hanna Bailey, David D. Stenehjem

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer por David D. Stenehjem, Dao Tran, Michael Nkrumah, Shilpa Gupta

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  3. 3
    Tumor mutational burden in lung cancer: a systematic literature review

    Tumor mutational burden in lung cancer: a systematic literature review por Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Zyczynski, Diana Brixner, David D. Stenehjem

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  4. 4
    Cancer incidence in immunocompromised patients: a single-center cohort study

    Cancer incidence in immunocompromised patients: a single-center cohort study por Sabrina Ilham, Connor Willis, Kibum Kim, Karen Chung, Brenda Wood, Malinda S. Tan, Chia Jie Tan, Danielle Nguyen, Diana Brixner, David D. Stenehjem

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer por David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma por James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal

    Publicado em 2017
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy

    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy por Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer por Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello

    Publicado em 2021
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: